RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
With Blockbuster Sales Potential
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.
You may also be interested in...
The French firm used a vaccines investor event to tout its respiratory syncytial virus prophylactic, Beyfortus, citing real-world data as well as a predictive model following recent questions about its utility in the face of advancing maternal vaccines.
Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.
Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.